Research Presentation Sessions: GI Tract
Novelties in hepatobiliary imaging
Lectures
1
Introduction by the moderator - Federica Vernuccio, Padova / IT
02:00
2
Is there any role for multiparametric MRI of the liver in follow-up of liver-transplant patients? - Benjamin Henninger, Innsbruck / AT
08:00
3
Golden-angle radial sparse parallel dynamic contrast enhanced MRI: automatic detection and characterisation of liver lesions using contrast agent behaviour - Manfred Meyer, Basel / CH
08:00
4
Quantification of hepatic steatosis with a novel attenuation imaging (ATI) ultrasound technique (QAI): preliminary findings on feasibility, reproducibility and diagnostic accuracy - Matteo Garcovich, Rome / IT
08:00
5
Virtual portal vein pressure gradient based on CFD model: a noninvasive procedure with CT angiography for the diagnosis of portal hypertension - Shang Wan, Cheng DU / CN
08:00
6
Prediction of hepatic decompensation in patients with primary sclerosing cholangitis using body composition model and machine learning-based combined topological and radiomics features - Yashbir Singh, Rochester / US
08:00
7
Assessment of clinical outcome in patients with portal hypertension: quantitative computed tomographic feature may serve as an effective biomarker - Shang Wan, Cheng DU / CN
08:00
8
Development and assessment of prognostic value and agreement of a novel MRCP-score for patients with primary sclerosing cholangitis - Aristeidis Grigoriadis, Stockholm / SE
08:00
9
Early tumour shrinkage as a novel imaging biomarker for patients with hepatocellular carcinoma undergoing immunotherapy - Felix Hahn, Mainz / DE
08:00
10
Evaluation of various methods of liver measurement in comparison to volumetric segmentation based on computed tomography - Maciej Cebula, Katowice / PL
08:00
11
The role of splenic volume as imaging biomarker in patients with hepatocellular carcinoma under immunotherapy - Felix Hahn, Mainz / DE
08:00
12
Myosteatosis can predict unfavourable outcomes in advanced hepatocellular carcinoma patients treated with hepatic artery infusion chemotherapy and anti-PD-1 immunotherapy - Xiaoping Yi, Changsha / CN
08:00
